AnaptysBio (NASDAQ:ANAB) Shares Down 8.2%

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) traded down 8.2% during trading on Friday . The company traded as low as $22.70 and last traded at $22.70. 158,350 shares traded hands during trading, a decline of 49% from the average session volume of 311,741 shares. The stock had previously closed at $24.73.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Wedbush upgraded AnaptysBio from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $20.00 to $34.00 in a report on Tuesday, March 12th. Wells Fargo & Company assumed coverage on AnaptysBio in a report on Thursday. They set an “overweight” rating and a $56.00 price objective for the company. Stifel Nicolaus assumed coverage on AnaptysBio in a report on Wednesday, February 21st. They set a “buy” rating and a $50.00 price objective for the company. Piper Sandler assumed coverage on AnaptysBio in a report on Friday, February 16th. They set an “overweight” rating and a $80.00 price objective for the company. Finally, BTIG Research assumed coverage on AnaptysBio in a report on Monday, February 26th. They issued a “buy” rating and a $55.00 price target for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, AnaptysBio presently has an average rating of “Moderate Buy” and an average price target of $46.13.

AnaptysBio Stock Performance

The stock has a market capitalization of $607.72 million, a price-to-earnings ratio of -3.74 and a beta of -0.30. The firm has a fifty day moving average of $23.53 and a 200-day moving average of $20.48.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.74) by $0.15. The firm had revenue of $9.01 million during the quarter, compared to the consensus estimate of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. On average, analysts predict that AnaptysBio, Inc. will post -6.25 EPS for the current year.

Insider Activity

In other news, CFO Dennis Mulroy sold 3,065 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $23.63, for a total transaction of $72,425.95. Following the completion of the sale, the chief financial officer now directly owns 964 shares in the company, valued at $22,779.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Daniel Faga sold 3,000 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the transaction, the chief executive officer now owns 749,087 shares of the company’s stock, valued at $16,045,443.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Dennis Mulroy sold 3,065 shares of the stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $23.63, for a total transaction of $72,425.95. Following the transaction, the chief financial officer now directly owns 964 shares in the company, valued at approximately $22,779.32. The disclosure for this sale can be found here. Insiders sold 157,005 shares of company stock worth $3,586,199 over the last ninety days. Corporate insiders own 35.50% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

A number of large investors have recently bought and sold shares of ANAB. Swiss National Bank lifted its holdings in AnaptysBio by 7.9% in the first quarter. Swiss National Bank now owns 42,300 shares of the biotechnology company’s stock worth $1,047,000 after acquiring an additional 3,100 shares during the last quarter. MetLife Investment Management LLC increased its stake in shares of AnaptysBio by 57.0% in the first quarter. MetLife Investment Management LLC now owns 11,043 shares of the biotechnology company’s stock valued at $273,000 after purchasing an additional 4,009 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of AnaptysBio by 11.0% in the first quarter. Dimensional Fund Advisors LP now owns 891,851 shares of the biotechnology company’s stock valued at $22,064,000 after purchasing an additional 88,457 shares during the period. Ergoteles LLC acquired a new stake in shares of AnaptysBio in the first quarter valued at approximately $479,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of AnaptysBio by 4.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 142,131 shares of the biotechnology company’s stock valued at $3,517,000 after purchasing an additional 5,819 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.